Launched Eli Lilly's Mounjaro® (tirzepatide) for obesity and diabetes in Thailand.
The launch of Mounjaro® in Thailand provides a much-needed advanced therapeutic option for the growing number of patients suffering from obesity and type 2 diabetes in the country. This aligns with regional efforts to combat the rising prevalence of these metabolic diseases, offering improved patient outcomes and quality of life through access to innovative treatments.
This product launch in Thailand addresses the significant and growing burden of obesity and diabetes in the APAC region, offering a new treatment option for patients.
Zuellig Pharma 已於泰國上市禮來公司（Eli Lilly）的創新肥胖症與糖尿病藥物 Mounjaro®（tirzepatide）。這標誌著在為管理這些慢性疾病的病患提供先進治療方案方面，邁出了重要一步，藉由 Zuellig Pharma 將新型藥物引進泰國市場的專業知識，以期改善病患照護。
健康科技与生物技术
此信号属于健康科技与生物技术频道。浏览相关信号，了解此发展如何融入更广泛的行业格局。
115 条频道信号Sign in to save notes on signals.
登录